NewsBenzingaArbutus Biopharma: BPA del tercer trimestre de $0.30 supera la estimación de $(0.03); ventas de $299.000K quedan por debajo de la estimación de $1.388M Arbutus Biopharma: BPA del tercer trimestre de $0.30 supera la estimación de $(0.03); ventas de $299.000K quedan por debajo de la estimación de $1.388M Benzinga 2026.11.10 12:50 (GMT+0) Open on Benzinga Other news Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says How to Play NKE Stock as Nike Risks Becoming a Forever Turnaround Story